This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Larry Hsu, Impax Laboratories President And Chief Executive Officer, To Retire

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Dr. Larry Hsu plans to retire as President and Chief Executive Officer of Impax Laboratories, Inc. Dr. Hsu will remain with the Company in his current position until a replacement CEO is hired; he will also remain a member of the Board of Directors following the appointment of his successor.

Dr. Allen Chao will lead a three-person search committee, which includes Dr. Hsu and Bob Burr, Chairman of the Board of Directors of Impax, to identify and hire Dr. Hsu’s replacement.

Dr. Hsu and the current management team will manage the Company through this transition period. The Board of Directors will be working closely with Dr. Hsu to ensure an orderly transition.

“Larry has been instrumental in every step of Impax' development. As co-founder and later CEO, he helped guide the Company from its founding in 1994, through the 1999 reverse merger with Global Pharmaceuticals that gave Impax its current shape, up through today,” said Bob Burr, Chairman of the Board of Directors of Impax. “Since becoming CEO in 2006, Larry has led Impax through an important period of substantial growth resulting in a four-fold increase in revenues, a strong balance sheet, initiating the Company’s brand strategy and successfully positioning the Company for long-term future growth.”

“The Board of Directors remains confident in and committed to the Company’s strategic direction. We are focused on finding a successor CEO that will lead Impax through its future growth,” Mr. Burr added. “During this time, we will remain focused on our highest corporate priority, promptly and successfully addressing our FDA compliance, while simultaneously continuing to execute on our core competencies in drug delivery expertise, formulation technology and our extensive experience in product development.”

“I am extremely proud of the many accomplishments Impax has realized over the past several years,” said Dr. Hsu. “I am truly grateful for the support I’ve received from the Board of Directors, the executive management team, our customers and our employees. I am confident Impax is well positioned to execute on its long-term business strategy. With an executive management team that boasts significant generic and brand industry experience, I know Impax is well positioned for great success in the future. I look forward to being a key participant in the process of selecting my successor as CEO and ensuring our future growth as a continuing member of the Board of Directors.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs